Caspase Inhibitors | Zendy

Nsikan Akpan | Zendy; Carol M. Troy | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Caspase Inhibitors

Author(s) -

Nsikan Akpan,

Carol M. Troy

Publication year - 2012

Publication title -

the neuroscientist

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.328

H-Index - 125

eISSN - 1089-4098

pISSN - 1073-8584

DOI - 10.1177/1073858412447875

Subject(s) - caspase , neuroprotection , proteases , neurodegeneration , apoptosis , stroke (engine) , neuroscience , inflammation , medicine , programmed cell death , pharmacology , disease , biology , bioinformatics , immunology , biochemistry , enzyme , mechanical engineering , engineering

In ischemic stroke, apoptosis persists for days to weeks after the onset of an ischemic event. Cysteine-ASPartic proteASEs (caspases) are key mediators of apoptosis and neurodegeneration in stroke. The impact of caspase activity is not restricted to neuronal death, as caspases can exacerbate inflammation and alter glial function. Thus, caspases are logical therapeutic targets for this disease, but they have never been clinically evaluated due to a paucity of ideal drug candidates. Recent developments in caspase inhibition and drug delivery offer novel neuroprotective strategies for stroke, which are deliberated in this review.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research